T1	Participants 0 29	Intravenous platelet blockade
T2	Participants 323 336	5362 patients
T3	Participants 774 873	185 of 2654 patients receiving cangrelor (7.0%) and in 210 of 2641 patients receiving placebo (8.0%
T4	Participants 1951 1975	intravenous ADP blockade
